Author

E. Andre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 6 Approach:experimental assay· 5 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Organism:bacteria (other)· 1 Research Focus:benchmarking· 1

Frequent Co-Authors

P. Maes· 5 shared J. Raymenants· 3 shared B. C. de Jong· 2 shared B. Slechten· 2 shared B. Vanmechelen· 2 shared C. J. Meehan· 2 shared C. Planchais· 2 shared D. Planas· 2 shared

Activity by Year

2018-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

P. Maes

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

D. Planas, T. Bruel, I. Staropoli, F. Guivel-Benhassine, F. Porrot, P. Maes, L. Grzelak, M. Prot, S. Mougari, C. Planchais, J. Puech, M. Saliba, R. Sahraoui, F. Femy, N. Morel, , O. Schwartz

This study evaluates the neutralizing antibody resistance of SARS-CoV-2 Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to monoclonal antibodies and sera from vaccinated individuals.

bioRxiv · Nov 17, 2022Microbiology

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

L. Vangeel, W. Chiu, S. De Jonghe, P. Maes, B. Slechten, J. Raymenants, E. Andre, P. Leyssen, J. Neyts, D. Jochmans

The paper evaluates the antiviral activity of remdesivir, molnupiravir, and nirmatrelvir against SARS-CoV-2 variants, finding they remain effective.

bioRxiv · Dec 27, 2021Microbiology

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

R. Abdelnabi, C. S.-Y. Foo, X. Zhang, V. Lemmens, P. Maes, B. Slechten, J. Raymenants, E. Andre, B. Weynand, K. Dallmeier, J. Neyts

This study shows that the omicron SARS-CoV-2 variant infects Syrian hamsters with significantly lower viral loads in the lungs compared to the D614G strain, with no detectable infectious virus.

bioRxiv · Dec 24, 2021Microbiology

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

D. Planas, N. Saunders, P. Maes, F. G. Benhassine, C. Planchais, F. Porrot, I. Staropoli, F. Lemoine, H. Pere, D. Veyer, J. Puech, J. Rodary, W. H. Bolland, J. Buchrieser, G. Baele, , O. Schwartz

This study shows that the Omicron variant of SARS-CoV-2 is resistant to most monoclonal antibodies and vaccine-induced antibodies, with reduced neutralization compared to Delta.

bioRxiv · Dec 14, 2021Immunology

A phylodynamic workflow to rapidly gain insights into the dispersal history and dynamics of SARS-CoV-2 lineages

S. Dellicour, K. Durkin, S. L. Hong, B. Vanmechelen, J. Marti-Carreras, M. S. Gill, C. Meex, S. Bontems, E. Andre, M. Gilbert, C. Walker, N. De Maio, N. R. Faria, J. Hadfield, M.-P. Hayette, , P. Maes

This paper introduces a phylodynamic workflow to analyze SARS-CoV-2 lineage dispersal, showing external introductions were key in Belgium and lockdowns had limited impact on transmission.

bioRxiv · May 5, 2020Evolutionary Biology

A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes region

J. C. Semuto Ngabonziza, C. Loiseau, M. Marceau, A. Jouet, F. Menardo, O. Tzfadia, R. Antoine, E. B. Niyigena, W. Mulders, K. Fissette, M. Diels, C. Gaudin, S. Duthoy, W. Ssengooba, E. Andre, , P. J. Supply

The paper identifies a new lineage of Mycobacterium tuberculosis complex, Lineage 8, found in the African Great Lakes region, and shows its evolutionary relationship to known lineages.

bioRxiv · Jan 20, 2020Microbiology

Xpert Ultra can unambiguously identify specific rifampicin resistance-conferring mutations

K. C. S. Ng, A. van Deun, C. J. Meehan, G. Torrea, M. Driesen, S. Gabriels, L. Rigouts, E. Andre, B. C. de Jong

The paper evaluates Xpert Ultra's ability to identify rifampicin resistance mutations by analyzing the relationship between rpoB mutations, Ultra probes, and melting temperature shifts.

bioRxiv · May 9, 2018Microbiology